If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Over the past two decades, a substantial body of pharmacovigilance research has documented case patterns of PML associated with this therapy. This page summarizes the key findings from published medical literature to help you understand the reported risks and monitoring strategies.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderately to severely active Crohn’s disease in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three known risk factors for its development in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefit when initiating and continuing therapy. The clinical presentation of PML is variable but often includes progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, memory impairment, cognitive disorder, and muscular weakness among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the spectrum of neurological symptoms that may overlap with PML or MS progression, complicating early detection.
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on the surface of immune cells, blocking their adhesion to endothelial cells and thereby preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in MS but also impairs normal immune surveillance of the brain, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination produces the clinical syndrome of PML. The risk is highest in patients with detectable anti-JCV antibodies, as seropositivity indicates prior exposure to the virus and potential for reactivation. Regarding the adequacy of warnings, the Tysabri label includes a boxed warning that clearly states the increased risk of PML and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that prescribers, patients, and pharmacies are educated about PML risk and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether warnings were sufficiently communicated to individual patients or whether risk factors were adequately assessed before treatment.
For patients in Michigan who have developed PML after Tysabri exposure, attorney-related considerations include the statute of limitations for filing a personal injury or product liability claim. In Michigan, the statute of limitations for personal injury actions is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For claims involving defective drugs, the discovery rule may apply, meaning the clock starts when the plaintiff knew or should have known that the drug caused the harm. Given that PML symptoms can be insidious and may initially be mistaken for an MS relapse, the timeline between exposure and documented harm is critical. The typical latency period for PML in Tysabri-treated patients is months to years, with risk increasing after two years of therapy. Patients diagnosed with PML should promptly consult legal counsel to determine the applicable filing deadline, as delays can bar recovery. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a mechanistic basis rooted in immune modulation. The label provides explicit warnings and mandates monitoring, but affected patients may still face challenges in timely diagnosis and legal recourse. Michigan residents who have suffered PML after Tysabri use should be aware of the three-year statute of limitations and the importance of early legal evaluation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Michigan, the statute of limitations for personal injury actions is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For claims involving defective drugs, the discovery rule may apply, meaning the clock starts when the plaintiff knew or should have known that the drug caused the harm. Given that PML symptoms can be insidious and may initially be mistaken for an MS relapse, the timeline between exposure and documented harm is critical. Patients diagnosed with PML should promptly consult legal counsel to determine the applicable filing deadline, as delays can bar recovery.
The Tysabri label identifies three known risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefit when initiating and continuing therapy.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.